Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux


Cite item

Full Text

Abstract

Aim. To study the role of serum surfactant protein D (SP-D) as a biomarker of lung injury in scleroderma systematica (SDS) in relation to the presence of gastroesophageal reflux (GER). Subjects and methods. Fifty-six patients (mean age 46±14 years) with diffuse and circumscribed SDS were examined and underwent pulmonary functional tests, X-ray and, if lung injury was present, high-resolution computed tomography of the lung, echocardiography, gastroduodenoscopy, and barium X-ray of the esophagus; an enzyme-linked immunosorbent assay was used to determine serum SP-D levels. Results. SP-D concentrations significantly correlate with the presence of lung injury in SDS and are significantly higher in the presence of pulmonary fibrosis and the signs of frosted glass and honeycomb lung patterns. SP-D levels were higher in the patients with lung injury and SDS in the group of those with pulmonary fibrosis and GER than in the group of pulmonary fibrosis patients without the latter. Conclusion. Serum SP-D may be considered in a number of biomarkers for the severity of lung injury in SDS, including GER-associated lung injury.

References

  1. Гусева Н.Г. Системная Склеродермия: Клиника, Диагностика, Лечение. Рос журн кож и вен бол 2002; 4: 5—15.
  2. Steen Vd. The Lung In Systemic Sclerosis. J Clin Rheumatol 2005; 11 (1): 40—46.
  3. Steen Vd., Medsger Ta. Changes In Causes Of Death In Systemic Sclerosis, 1972—2002. Ann Rheum Dis 2007; 66 (7): 940—944.
  4. Коган Е.А., Коренев Б.М., Попова Е.Н. и др. Интерстициальные болезни легких. М: Литтерра 2007; 186—191.
  5. Ананьева Л.П., Теплова Л.В., Лесняк В.Н. и др. Клиническая Оценка проявлений интерстициального поражения легких при системной склеродермии по данным компьютерной томографии высокого разрешения. Науч-практ ревматол 2011; 2: 30—39.
  6. Schurawitzki H., Stiglbauer R., Graninger W. et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution ct versus radiography. Radiology 1990; 176 (3): 755—759.
  7. Assassi S., Sharif R., Lasky Re. et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the genisos cohort. Arthritis Res Ther 2010; 12 (5): R166.
  8. Goldin Jg., Lynch Da., Strollo Dc. et al. High-resolution ct scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134 (2): 358—367.
  9. Launay D., Remy-Jardin M., Michon-Pasturel U. et al. High-resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33 (9): 1789—1801.
  10. Wells Au., Steen V., Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: Iii40—44.
  11. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62 (2): 97—99.
  12. Wells Au., Hansell Dm., Rubens Mb. et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40 (7): 1229—1236.
  13. Clements Pj., Goldin Jg., Kleerup Ec. et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004; 50 (6): 1909—1917.
  14. Elhaj M., Charles J., Pedroza C. et al. Can serum surfactant protein d or cc-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013; 40 (7): 1114—1120.
  15. Kuroki Y., Sano H., Sohma H., Akino T. Pulmonary Surfactant Proteins: Structure, Function, Pathophysiology. Tanpakushitsu Kakusan Koso 1998; 43 (7): 834—846.
  16. Hasegawa Y., Takahashi M., Ariki S. et al. Surfactant Protein D Suppresses Lung Cancer Progression By Downregulation Of Epidermal Growth Factor Signaling. Oncogene 2014 Mar 10. [Epub Ahead Of Print]
  17. Pastva Am., Wright Jr., Williams Kl. Immunomodulatory Roles Of Surfactant Proteins A And D: Implications In Lung Disease. Proc Am Thorac Soc 2007; 4 (3): 252—257.
  18. Kumánovics G., Minier T., Radics J. et al. Comprehensive Investigation Of Novel Serum Markers Of Pulmonary Fibrosis Associated With Systemic Sclerosis And Dermato/Polymyositis. Clin Exp Rheumatol 2008; 26 (3): 414—420.
  19. Maeda M., Ichiki Y., Aoyama Y., Kitajima Y. Surfactant Protein D (Sp-D) And Systemic Scleroderma (Ssc). J. Dermatol 2001; 28 (9): 467—474.
  20. Takahashi H., Abe S., Kuroki Y. Pulmonary Surfactant Proteins (Sp-A, Sp-D). Nippon Rinsho 2004; 62 (Suppl 11): 325—328.
  21. Takahashi H., Kuroki Y., Tanaka H. et al. Serum Levels Of Surfactant Proteins A And D Are Useful Biomarkers For Interstitial Lung Disease In Patients With Progressive Systemic Sclerosis. Am J Respir Crit Care Med 2000; 162 (1): 258—263. doi: 10.1164/Ajrccm.162.1.9903014.
  22. Greene K., King T., Kuroki Y. et al. Serum Surfactant Proteins-A And -D As Biomarkers In Idiopathic Pulmonary Fibrosis. Eur Respir J 2002; 19 (3): 439—446.
  23. Van Den Hoogen F., Khanna D., Fransen J. et al. Classification Criteria For Systemic Sclerosis: An American College Of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65 (11): 2737—2747.
  24. Leroy Ec., Black C., Fleischmajer R. et al. Scleroderma (Systemic Sclerosis): Classification, Subsets And Pathogenesis. J Rheumatol 1988; 15 (2): 202—205.
  25. Asano Y., Ihn H., Yamane K. et al. Clinical Significance Of Surfactant Protein D As A Serum Marker For Evaluating Pulmonary Fibrosis In Patients With Systemic Sclerosis. Arthritis Rheum 2001; 44 (6): 1363—1369.
  26. Hant Fn., Ludwicka-Bradley A., Wang H. et al. Surfactant Protein D And Kl-6 As Serum Biomarkers Of Interstitial Lung Disease In Patients With Scleroderma. J Rheumatol 2009; 36 (4): 773—780.
  27. Bonella F., Volpe A., Caramaschi P. et al. Surfactant Protein D And Kl-6 Serum Levels In Systemic Sclerosis: Correlation With Lung And Systemic Involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (1): 27—33.
  28. Cheng G., Ueda T., Numao T. et al. Increased Levels Of Surfactant Protein A And D In Bronchoalveolar Lavage Fluids In Patients With Bronchial Asthma. Eur Respir J 2000; 16 (5): 831—835.
  29. Yanaba K., Hasegawa M., Takehara K., Sato S. Comparative Study Of Serum Surfactant Protein-D And Kl-6 Concentrations In Patients With Systemic Sclerosis As Markers For Monitoring The Activity Of Pulmonary Fibrosis. J Rheumatol 2004; 31 (6): 1112—1120.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies